X

Stock Analysis

Evaluated by users | BSE: | NSE: |
Super Religare Laboratories Limited was initially incorporated on July 7, 1995 as specialty Ranbaxy Private Limited, 50:50 joint ventures between Specialty Laboratories Asia Limited and Ranbaxy Laboratories Limited, pursuant to a joint venture agreement dated April 17, 1995 (JV Agreement)....

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Information and data for this Company is currently unavailable.
We assure our users that information and data for the company will be available soon.
Key Financial Ratios
No Data To Display
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Super Religare Laboratories Limited was initially incorporated on July 7, 1995 as specialty Ranbaxy Private Limited, 50:50 joint ventures between Specialty Laboratories Asia Limited and Ranbaxy Laboratories Limited, pursuant to a joint venture agreement dated April 17, 1995 (JV Agreement). Later the name of the company was subsequently changed to  SRL Ranbaxy Limited .The reason for such name change was the termination of the joint venture with Specialty Laboratories Asia

Super Religare Laboratories Limited was initially incorporated on July 7, 1995 as specialty Ranbaxy Private Limited, 50:50 joint ventures between Specialty Laboratories Asia Limited and Ranbaxy Laboratories Limited, pursuant to a joint venture agreement dated April 17, 1995 (JV Agreement). Later the name of the company was subsequently changed to  SRL Ranbaxy Limited .The reason for such name change was the termination of the joint venture with Specialty Laboratories Asia Limited on January 18, 2002, consequent to which the company had to drop the trade name specialty  from its name, in accordance with the JV Agreement.

On August 20, 2010, the company acquired 100% of the paid up capital of Piramal Diagnostics Services Private Limited (PDSPL). The company was incorporated in order to undertake the business of establishing, maintaining and managing clinical reference laboratories to provide testing, diagnostic and prognostic monitoring services.

Business Profile:

The company is one of the leading diagnostics services companies in India. Following the acquisition of PDSPL in August 2010, we have the largest market share (48%) in the organized sector in India. The company provides diagnostic testing services (routine, specialized and esoteric tests), preventive care testing services and clinical research trial testing services at their laboratories, and during the nine month period ended December 31, 2010 it has performed approximately 33,000 diagnostic tests per day. It has served more than 4.20 million customers during the nine month period ended December 31, 2010 through their network of reference laboratories, Centers of Excellence, network laboratories (comprising pathology and radiology laboratories), collection centers and wellness centers. As of December 31, 2010, its diagnostic laboratory network comprised eight reference laboratories, seven Centers of Excellence, 181 network laboratories (comprising 164 pathology laboratories and 17 radiology laboratories), 15 wellness centers and 888 collection centers. As of December 31, 2010, of its 164 pathology laboratories, 53 are owned by the company, it operate and manage 31 pathology laboratories based in hospitals (14 of which are based in hospitals run by Fortis Healthcare Limited), 55 are joint venture laboratories and 25 are franchisee laboratories. As of December 31, 2010, of its 17 radiology laboratories, 16 are owned by them and we operate and manage one radiology laboratory based in a hospital. Six of its reference laboratories are based in India, its seventh reference laboratory is based in Kathmandu, Nepal and the company has entered into a service agreement for one reference laboratory in the Dubai Healthcare City.

In addition, currently it is having 23 collection centers, as well as representation and liaison offices, outside India in the United Arab Emirates, Oman, Qatar, Kuwait, Bahrain, Sri Lanka, Bangladesh, Nepal, the Maldives, Tanzania and Zambia.

The company’s reports are used for detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions, as well as to monitor and evaluate responses to medication. Through Piramal Diagnostics, it offer a range of pathology services and radiology modalities including computed tomography (CT), diagnostic radiology (X-ray), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET). Its collection centers collect specimens within an area or region for shipment to a pre-designated laboratory for testing and its wellness centers offer inter alia preventive care through various health screening packages.

The company also provides clinical research services, which are dedicated to offering centralized laboratory services to support the needs of drug development for various phases of clinical trials conducted by Indian as well as international pharmaceutical, biotechnological and research companies. Its services extend to support multi-centric studies at sites within India as well as in their neighboring Asian countries.

Top 5 Group Companies:

  • Fortis Healthcare Limited
  • Fortis Malar Hospitals Limited
  • Religare Enterprises Limited
  • Dion Global Solutions Limited - one of the largest Group Company (based on turnover- Fiscal 2010)
  • Religare Securities Limited
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback